Document is current
Any future updates will be listed below
-
Authors
De Winter, Derek P http://orcid.org/0000-0002-4820-143X
Hulzebos, Christian http://orcid.org/0000-0002-8159-7501
Van ‘t Oever, Renske M http://orcid.org/0000-0002-8981-9500
De Haas, Masja http://orcid.org/0000-0002-7044-0525
Verweij, EJT http://orcid.org/0000-0002-9343-9957
Lopriore, Enrico http://orcid.org/0000-0002-3513-5066
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 17 October 2022
Revised: 17 November 2022
Accepted: 18 November 2022
First Online: 5 December 2022
Declarations
:
: Not applicable
: Not applicable
: Not applicable
: Derek P. de Winter, PhD candidate, is funded by Momenta Pharmaceuticals, Inc., which was acquired by Johnson & Johnson, and is a coordinating investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. Renske M van ‘t Oever is a coordinating investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. Joanne EJT Verweij is the principal investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals. Enrico Lopriore is a sub-investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals.
